AdnaTest OvarianCancerSelect

Immunomagnetic cell enrichment forms the core of the QIAGEN AdnaTest OvarianCancerSelect workflow, which pulls circulating tumor cells out of peripheral blood samples ahead of molecular characterization. Antibody-conjugated magnetic beads selectively capture epithelial and ovarian tumor-associated antigens on rare circulating cells, retaining them against a magnetic rack while non-target leukocytes wash away. The enriched cell fraction is then lysed, and the released mRNA feeds directly into reverse transcription and PCR amplification using the matched AdnaTest OvarianCancerDetect reagent set.

Applied in liquid biopsy investigations of ovarian carcinoma, this single-use kit supports in vitro research workflows and depends on refrigerated reagents to preserve antibody-bead activity throughout processing. A 5 mL whole blood draw serves as the starting input, and hands-on processing typically requires around four hours before transitioning to PCR amplification of transcripts such as EpCAM, MUC1, and ERBB2. Researchers evaluate enrichment success by band intensity on an agarose gel, where positive signals confirm the presence of tumor-derived mRNA in the captured fraction, while negative samples show no amplification product at the expected size.